Exact FDA event identifier

Event 85773

1 recalled-product record grouped only because every row carries this exact official event ID.

Event summary

Timeline bucket: May 28, 2020
Product types: Drug
Classifications: Class II
Statuses: Terminated
Recalling firm wording: QuVa Pharma, Inc.

Dossier provenance

Source snapshots represented here

openFDA Drug Enforcement Report-date coverage June 20, 2012–July 08, 2026 Known gap: openFDA describes 2004-present coverage, but the current export has no report-date records in this interval.

Enforcement coverage uses report dates; product initiation dates can precede those bounds. Device-enrichment coverage uses FDA event_date_initiated.

How coverage and grouping work

Device root-cause evidence is not applicable to this event. No grouped product has the official product type device; this is not an unavailable-enrichment finding.

Complete imported group

Every recalled product in this event

1 official enforcement rows

Product dates, classifications, firms, and source wording remain attached to their individual rows. Opening this dossier never hides products that did not match a prior timeline filter.

drug · product 1 of 1

oxyTOCIN 30 Units/500 mL (0.06 Units/mL) added to 0.9% Sodium Chloride Injection for IV Use, Rx only, QuVa Pharma 1075 West Park One Drive, Suite 100 Sugar Land, TX 77478 888-339-0874, NDC 70092-1068-07

D-1302-2020

Recall number: D-1302-2020
Initiated: May 28, 2020
Classification: Class II
Status: Terminated
Recalling firm: QuVa Pharma, Inc.
Quantity: 648 bags

App-derived interpretation

Potency or specification failure reason.potency_specification_failure · v1.0.0

Subpotent

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Subpotent drug - Product did not contain drug.

Code information

Lot#: 30010515

Distribution pattern

USA Nationwide